Drawing for RYLENTIX

USPTO serial 87510865

RYLENTIX

Reviewed by CopyMark Law Group

Reg. 5754281Status 710
Filing date
Status date
Registration date
May 21, 2019
Examiner
RINGLE, JAMES W
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with RYLENTIX?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

John O'Malley

JOHN O'MALLEY VOLPE AND KOENIG, P.C.30 SOUTH 17TH STREETSUITE 1800PHILADELPHIA, PA 19103

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of pain, bone metabolic pathologies and osteo-articular pathologies; pharmaceutical preparations for the treatment of pain, bone metabolic pathologies and osteo-articular pathologies containing neridronic acid and/or its salts thereof; pharmaceutical preparations for the treatment of pain, bone metabolic pathologies and osteo-articular pathologies, namely, neridronic acid and/or its salts thereof; pharmaceutical preparations for the treatment of pain, bone metabolic pathologies and osteo-articular pathologies containing neridronate sodium; pharmaceutical preparations for the treatment of pain, bone metabolic pathologies and osteo-articular pathologies, namely, neridronate sodiumSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Dec 5, 2025C8..CANCELLED SEC. 8 (6-YR)—
May 21, 2024REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 21, 2019R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 14, 2019ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Jan 3, 2019ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Dec 4, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 4, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 14, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 29, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 29, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Oct 29, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Oct 17, 2018ALIEASSIGNED TO LIE—
Oct 8, 2018ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Oct 8, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Apr 9, 2018GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Apr 9, 2018GNSIINQUIRY TO SUSPENSION E-MAILED—
Apr 9, 2018CNSISUSPENSION INQUIRY WRITTEN—
Oct 9, 2017GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Oct 9, 2017GNSLLETTER OF SUSPENSION E-MAILED—
Oct 9, 2017CNSLSUSPENSION LETTER WRITTEN—
Sep 26, 2017DOCKASSIGNED TO EXAMINER—
Jul 7, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 3, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance